Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current topics on low-density lipoprotein apheresis.

R Bambauer1, R Schiel, R Latza

  • 1Institute for Blood Purification, Homburg/Saar, Germany.

Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis
|November 29, 2001
PubMed
Summary

Low-density lipoprotein (LDL) apheresis is an effective treatment for severe hyperlipidemia and coronary heart disease (CHD) refractory to conventional therapies. Immunoadsorption shows particular efficacy for elevated lipoprotein (a) [Lp(a)] levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Quality of Diabetes Care and Morbidity over 20 Years in People with Type 1 Diabetes and Long Diabetes Duration: The JEVIN Trial.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2016
Same author

Use and Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Insulin Injection Therapy (MIT) in Children, Adolescents and Young Adults with Type 1 Diabetes Mellitus.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2016
Same author

An innovative telemedical support system to measure physical activity in children and adolescents with type 1 diabetes mellitus.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2011
Same author

Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).

Clinical nephrology·2008
Same author

Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2007
Same author

Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2007

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Vascular Medicine

Background:

  • Severe hyperlipidemia (HLP) and elevated lipoprotein (a) [Lp(a)] levels, often with coronary heart disease (CHD), pose poor prognoses despite diet and lipid-lowering drugs.
  • Atherosclerosis remains a leading cause of mortality, with hyperlipidemia as a key risk factor.
  • Established risk factors include smoking, hypertension, diabetes, and obesity, highlighting the need for aggressive lipoprotein reduction.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-density lipoprotein (LDL) apheresis for patients with severe HLP and CHD unresponsive to maximal conventional therapy.
  • To compare the effectiveness of different LDL apheresis systems, particularly concerning Lp(a) reduction.

Main Methods:

  • Review of published data on four LDL apheresis systems: immunoadsorption, heparin-induced extracorporeal LDL/fibrinogen precipitation, dextran sulfate LDL-adsorption, and LDL-hemoperfusion.

Related Experiment Videos

  • Analysis of clinical outcomes, including lipid profiles (total cholesterol, LDL, HDL, triglycerides) and Lp(a) levels.

    • Main Results:

    • LDL apheresis is effective and safe for long-term treatment of severe HLP refractory to maximal conservative therapy.
    • No significant differences were observed among LDL apheresis systems regarding overall clinical outcomes or standard lipid parameters.
    • Immunoadsorption demonstrated superior effectiveness in reducing elevated Lp(a) levels.

    Conclusions:

    • LDL apheresis is a valuable therapeutic option for severe hyperlipidemia and associated CHD when standard treatments fail.
    • The choice of apheresis system may be tailored, with immunoadsorption being preferred for patients with elevated Lp(a).
    • Continued application of LDL apheresis offers a safe and effective strategy for managing refractory hyperlipidemia and reducing cardiovascular risk.